Payment overview · 2025
General Payments
$26,518.84
223 reported records · 16 companies
Healthcare provider profile · identity verified
Robert Orin Holmes, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · POLLOCKSVILLE, NC · NPI 1053496349
Verified facts
What the public records show
CMS Open Payments records show Robert Orin Holmes, D.O. received $26,518.84 in general payments during 2025 across 223 reported records.
ABBVIE INC. accounted for 73.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Actemra, Acthar, Benlysta, Otezla, Rinvoq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 318 claims for Rinvoq by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Otezla by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Actemra as an associated drug or biological on 2116 records involving 1314 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Actemra by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Benlysta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OLUMIANT as an associated drug or biological on 560 records involving 277 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Olumiant by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Mallinckrodt Hospital Products Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ACTHAR as an associated drug or biological on 35914 records involving 11592 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Acthar by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19,537.65 | 73.7% | 49 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $4,549.82 | 17.2% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $755.30 | 2.9% | 47 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $332.56 | 1.2% | 23 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $211.16 | 0.8% | 25 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $187.56 | 0.7% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $149.95 | 0.6% | 17 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $144.39 | 0.5% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $139.53 | 0.5% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $123.58 | 0.5% | 6 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $121.72 | 0.5% | 5 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $98.20 | 0.4% | 4 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $66.21 | 0.2% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $64.61 | 0.2% | 3 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $21.37 | 0.1% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $15.23 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,625.00 | 10 |
| Food and Beverage | $3,478.89 | 210 |
| Travel and Lodging | $3,414.95 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $16,610.75 | 33 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $4,549.82 | 11 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $2,926.90 | 16 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $332.56 | 23 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $284.74 | 15 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $263.05 | 19 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $211.16 | 25 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $187.56 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $149.95 | 17 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $144.39 | 8 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $133.04 | 9 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $108.21 | 5 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $102.21 | 5 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $98.20 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $75.44 | 6 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $66.21 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $64.61 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $11.06 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $6.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Actemra actemra |
2025 | Actemra | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ACTHAR acthar |
2025 | Acthar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 318 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
318 | 42 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Actemra open payments reported associated product |
CMS Open Payments — General Payments 2116 supporting records · 1314 recipient NPIs · example record 1211488494 |
Actemra · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | OLUMIANT open payments reported associated product |
CMS Open Payments — General Payments 560 supporting records · 277 recipient NPIs · example record 1186464669 |
Olumiant · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Mallinckrodt Hospital Products Inc. Exact reporting entity; no affiliate inference |
2025 | ACTHAR open payments reported associated product |
CMS Open Payments — General Payments 35914 supporting records · 11592 recipient NPIs · example record 1211945432 |
Acthar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Methotrexate | Methotrexate Sodium | 477 | 106 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 466 | 114 |
| Allopurinol | Allopurinol | 434 | 98 |
| Rinvoq | Upadacitinib | 318 | 42 |
| Prednisone | Prednisone | 211 | 63 |
| Omeprazole | Omeprazole | 145 | 41 |
| Gabapentin | Gabapentin | 139 | 31 |
| Orencia Clickject | Abatacept | 118 | 12 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 106 | 21 |
| Kevzara | Sarilumab | 105 | 15 |
| Humira(Cf) Pen | Adalimumab | 96 | 16 |
| Tramadol Hcl | Tramadol Hcl | 88 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 14 |
| Folic Acid | Folic Acid | 71 | 22 |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 63 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 63 | 16 |
| Methylprednisolone | Methylprednisolone | 61 | 36 |
| Valacyclovir | Valacyclovir Hcl | 60 | 23 |
| Celecoxib | Celecoxib | 59 | 14 |
| Actemra Actpen | Tocilizumab | 53 | suppressed |
| Cosentyx Sensoready Pen | Secukinumab | 53 | suppressed |
| Telmisartan | Telmisartan | 48 | suppressed |
| Meloxicam | Meloxicam | 47 | 12 |
| Amlodipine Besylate | Amlodipine Besylate | 46 | suppressed |
| Skyrizi Pen | Risankizumab-Rzaa | 46 | 15 |
| Xeljanz Xr | Tofacitinib Citrate | 46 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Enbrel Sureclick | Etanercept | 36 | suppressed |
| Furosemide | Furosemide | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | 11 |
| Atorvastatin Calcium | Atorvastatin Calcium | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 14 |
| Benlysta | Belimumab | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 23 |
| Otezla | Apremilast | 32 | suppressed |
| Colchicine | Colchicine | 31 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Losartan Potassium | Losartan Potassium | 28 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Taltz Autoinjector | Ixekizumab | 26 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Olumiant | Baricitinib | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 13 |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Acthar | Corticotropin | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Cosentyx Unoready Pen | Secukinumab | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Leflunomide | Leflunomide | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Eliquis | Apixaban | 17 | suppressed |
| Lisinopril | Lisinopril | 17 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Actemra | Tocilizumab | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Cosentyx (2 Syringes) | Secukinumab | 13 | suppressed |
| Enbrel | Etanercept | 13 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Fondaparinux Sodium | Fondaparinux Sodium | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Orencia | Abatacept | 12 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $26,518.84 · 223 records | ABBVIE INC. | ACTHAR, Actemra, BENLYSTA, Bimzelx, COSENTYX, EVENITY, KRYSTEXXA, Kerendia, LUPKYNIS, OTEZLA, PURIFIED CORTROPHIN GEL, RINVOQ, SAPHNELO, SHINGRIX, SKYRIZI, TALTZ, TAVNEOS, TWIIST, Tymlos, UPLIZNA, XELJANZ, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Actemra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error